RMTI Rockwell Medical

Shareholders Resoundingly Vote to Support Richmond / Ravich Case for Change at Rockwell Medical

Richmond Brothers, Inc., a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell” or the “Company”), and Mark H. Ravich, who together with their affiliates beneficially own nearly 6.1 million shares, or 11.7% of the Company’s outstanding common stock, today announced that, based on the preliminary report provided by their proxy solicitor, Rockwell shareholders have overwhelmingly voted to elect Richmond / Ravich’s highly-qualified nominee, Mark H. Ravich, to the Company’s Board at the 2017 Annual Meeting of Shareholders, which was held today.

David S. Richmond, Chairman of Richmond Brothers, Inc., and Mark H. Ravich issued the following statement commenting on the results:

“First and foremost, we would like to express our sincere gratitude to the many Rockwell shareholders – including the largest institutional holders – who have embraced our efforts to bring true change to the Company. The preliminary results from today’s vote are a strong indication of shareholders’ frustration with the performance and governance issues that have characterized Rockwell for years – and a powerful referendum that immediate change is needed at the Company. Needless to say, we are very pleased with this groundswell of support from our fellow shareholders, coupled with the endorsements we received from the three leading, independent proxy advisory firms – ISS, Glass Lewis and Egan Jones. We look forward to Mark bringing a true shareholder perspective and ownership mentality to the Rockwell Board – and we hope that the Company can take the steps that are necessary to change course at this critical moment.”

Final results of the Annual Meeting will be published by the Company once they are certified by the Company’s inspector of elections.

For more information, and to see other communications and filings from Richmond Brothers and Mark H. Ravich, visit this link: http://www.richmondbrothers.com/time-for-action-at-rmti.

About Richmond Brothers, Inc.

Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994.

About Mark H. Ravich

Mark H. Ravich is a private investor and currently serves as President of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998.

EN
01/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rockwell Medical

 PRESS RELEASE

Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...

 PRESS RELEASE

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...

 PRESS RELEASE

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch